Persistence of antibodies three years after vaccination with the 23-valent pneumococcal vaccine

M. Campins Martí, J. Casal Lombos, D. Tarragó Asensio, M. J. Rodrigo Anoro, A. Allepuz Palau, L. Callís Bracons

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


Objective: To study the persistence of antibodies after primary immunization with the 23-valent pneumococcal vaccine in children with nephrotic syndrome. Methods: Sera from 14 of 26 children with nephrotic syndrome were obtained 3 years after vaccination. We used an ELISA method to measure IgG antibody levels to pneumococcal serotypes 14, 23F, 3 and 6B. Antibody levels before vaccination, 1 month and 3 years after vaccination were compared. Results: Significant increases in specific antibody concentrations were observed 30 days after vaccination for all serotypes except serotype 3. Differences in response according to serotype were found. The highest serological response was observed for serotype 14 (78.5% of the patients showed a good-to-moderate response). Three years after vaccination antibody levels were significantly decreased (27.3% of children for serotype 14, 46.2% for serotype 23F and 50% for serotype 6B). Conclusions: The 23-valent pneumococcal vaccine is immunogenic in children aged more than 2 years with nephrotic syndrome. Response varied according to serotype. Persistence of vaccine-induced antibodies is short-term, with low antibody levels 3 years after immunization. The results of this study suggest that these patients require revaccination 3 years after the first dose.
Original languageEnglish
Pages (from-to)184-187
JournalAnales de Pediatria
Issue number2
Publication statusPublished - 1 Jan 2003


  • 23-Valent pneumococcal vaccine
  • Antibody persistence
  • Nephrotic syndrome
  • Revaccination


Dive into the research topics of 'Persistence of antibodies three years after vaccination with the 23-valent pneumococcal vaccine'. Together they form a unique fingerprint.

Cite this